ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity

BACKGROUND: IBI362, a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week weight loss up to 6.4% at doses up to 6 mg in Chinese participants with overweight or obesity. We further explored the safety and efficacy of IBI362 dosed up to 9 mg and 10 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Linong, Jiang, Hongwei, Yang, Jing, Yu, Lei, Cai, Chenghang, Liu, Meng, Deng, Huan, Feng, Liqi, Qian, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Adipose Tissue, Appetite, & Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624873/
http://dx.doi.org/10.1210/jendso/bvac150.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624873/
http://dx.doi.org/10.1210/jendso/bvac150.026

Ejemplares similares